NICE’s Accelerated Drug Approval Process Aims to Overcome COVID-19 Delays

The UK’s National Institute for Health and Care Excellence (NICE) has announced an accelerated approval process that is intended to address challenges in drug approval due to the COVID-19 pandemic. Since the program’s implementation, plaque psoriasis drug bimekizumab has been approved.

“The procedure has had early success, with a pilot trial permitting the approval of bimekizumab, an antibody useful in treating severe plaque psoriasis. As of the second of August, provisional advice was released by NICE indicating that bimekizumab may be used to treat psoriasis due to comparative effectiveness research demonstrating its effectiveness.” Read more here.

(Source: Darcy Hodge, The Evidence Base, 8/18/21)